Actively Recruiting
Phase 1 Study of Tocilizumab-aazg TYENNE for Treatment of Aneurysmal Subarachnoid Hemorrhage to Reduce Stroke Risk
Led by University of Florida · Updated on 2026-03-04
30
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating tocilizumab-aazg TYENNE for patients who have had a burst brain aneurysm, known as aneurysmal subarachnoid hemorrhage. The study aims to assess the safety of this medication and to explore whether it might help prevent strokes caused by delayed cerebral ischemia in these patients. This is an open-label Phase 1 trial conducted at a single center. Participants will receive a single intravenous infusion of tocilizumab-aazg at a dose of 6 mg per kilogram of body weight on Day 0 after their aneurysmal hemorrhage and enrollment. The trial involves no placebo or comparison group, focusing on monitoring effects after this infusion. The treatment is designed to be given shortly after symptom onset, within 24 hours. During the study, participants will be closely monitored for safety and potential side effects up to 90 days after the infusion. Researchers will track liver enzyme levels, blood cell counts, adverse events, and mortality rates. Participants will also have to comply with follow-up visits and undergo laboratory tests and clinical evaluations to assess their condition and response to the treatment throughout the trial period.
CONDITIONS
Brief Title
Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events
Research Team
B
Brian Hoh, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
